Natural Capsules Ltd.

BSE: NATCAPSUQ524654ISIN INE936B01015

Healthcare
Pharmaceuticals

Share price

₹133.20-2.75 (-2.02%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹237.00
52W low: ₹132.00
Off 52W high: -43.80%
1M return: -20.67%
3M return: -9.60%
6M return: -13.59%
1Y return: -37.35%
20D avg volume: 1,279
50 DMA: ₹170.71
200 DMA: ₹160.48

Key ratios Consolidated

Market cap: ₹138.68 Cr
Current price: ₹133.20
52W high / low: ₹237.00 / ₹132.00
Face value: ₹10.00
P/E: -5.59
P/B: 0.62
EPS (TTM): ₹-23.85
Book value / share: ₹213.39
ROE: —
ROCE: -5.80%
Operating margin: —
Net margin: —
Debt / equity: 0.49
Net debt: ₹114.12 Cr
Interest cover: -1.55
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 82.5 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	48.71	58.45	37.75	45.80	45.20	44.97	43.83	41.23	39.18	—
	2.35	0.76	0.45	0.16	0.36	0.30	0.11	0.11	0.18	—
	51.06	59.22	38.19	45.96	45.56	45.27	43.94	41.33	39.36	—
	56.90	64.29	47.28	53.66	51.63	44.38	43.44	40.72	38.59	—
	28.92	29.47	25.34	24.84	23.58	22.95	22.31	21.24	20.38	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	5.24	5.48	5.73	5.55	5.38	3.71	3.82	3.29	3.31	—
	4.97	2.89	2.85	2.68	2.53	1.64	1.54	1.65	1.49	—
	4.33	4.28	4.36	4.29	4.21	2.16	2.33	2.35	2.28	—
	16.40	16.16	15.37	16.82	15.93	14.07	13.46	13.60	11.53	—
	-5.83	-5.08	-9.08	-7.70	-6.06	0.89	0.50	0.62	0.77	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	-5.83	-5.08	-9.08	-7.69	-6.06	0.89	0.50	0.62	0.77	—
	0.09	-0.10	-1.97	0.71	0.48	0.37	0.40	1.23	0.17	—
	-5.74	-4.98	-7.12	-6.99	-5.58	0.52	0.11	-0.61	0.60	—
	-5.55	-4.82	-6.88	-6.76	-5.40	0.13	0.10	-0.60	0.65	—
Key metrics
	3.47	2.09	-1.87	-0.72	0.68	4.69	4.37	4.62	4.54	—
	7.10%	3.60%	-5.00%	-1.60%	1.50%	10.40%	10.00%	11.20%	11.60%	—
	-11.80%	-8.50%	-18.90%	-15.30%	-12.30%	1.20%	0.30%	-1.50%	1.50%	—
	—	-0.80%	—	-1.60%	—	0.80%	—	—	—	—
	7.80%	30.00%	-13.90%	11.10%	15.40%	—	—	—	—	—
	-2.90%	-1,057.70%	-6,572.70%	-1,045.90%	-1,030.00%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	190.71	187.21	169.21	—
	3.72	1.73	0.70	—
	194.43	188.94	169.91	—
	222.13	216.86	167.12	—
	108.57	103.23	86.88	—
	0.00	0.00	0.00	—
	22.00	21.00	14.13	—
	13.39	10.95	6.31	—
	17.26	17.14	9.12	—
	64.75	65.41	52.65	—
	-27.69	-27.92	2.79	—
	0.00	0.00	0.00	—
	-27.68	-27.92	2.79	—
	-1.27	-3.26	2.17	—
	-24.83	-24.66	0.62	—
	-24.01	-23.84	0.22	—
Key metrics
	2.97	0.17	18.22	—
	1.56%	0.10%	10.80%	—
	-13.02%	-13.20%	0.40%	—
	—	-5.80%	2.80%	—
	8.83%	10.60%	—	—
	—	-4,077.40%	—	—
	—	-0.61	-17.88	—
	—	-0.44	43.15	—
	—	0.49	0.40	—
	—	114.12	103.11	—
	—	82.5	106.1	—
Balance sheet
	—	424.16	419.35	—
	—	136.80	129.59	—
	—	0.22	0.69	—
	—	71.35	62.24	—
	—	26.33	25.46	—
	—	34.29	0.00	—
	—	273.33	282.33	—
	—	55.32	38.51	—
	—	132.73	99.99	—
	—	114.34	103.80	—
	—	59.62	47.40	—
	—	54.72	56.40	—
	—	234.72	257.16	—
Cash flow
	—	10.92	26.75	—
	—	-10.77	-44.48	—
	—	-0.62	16.17	—
	—	11.53	44.63	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	43.02	50.80	34.15	44.58	44.24	44.36	43.41	41.03	39.14	—
	2.31	2.13	2.11	1.73	1.69	1.55	1.15	0.77	0.76	—
	45.33	52.93	36.25	46.31	45.93	45.91	44.56	41.80	39.90	—
	39.67	45.49	35.80	42.61	42.46	42.78	42.35	39.78	37.96	—
	21.73	21.56	20.94	22.82	22.10	22.13	21.46	21.11	20.42	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	3.34	4.06	3.91	3.70	3.61	3.58	3.72	3.21	3.23	—
	1.44	1.49	1.45	1.45	1.36	1.52	1.39	1.54	1.46	—
	2.10	2.06	2.09	2.02	1.99	1.94	2.14	2.16	2.09	—
	12.35	12.16	12.09	12.94	12.75	13.38	13.11	13.19	11.22	—
	5.66	7.43	0.46	3.70	3.48	3.13	2.21	2.02	1.94	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	5.66	7.43	0.46	3.70	3.48	3.13	2.21	2.02	1.94	—
	1.63	1.91	0.10	0.89	0.95	0.51	0.51	1.09	0.48	—
	4.04	5.52	0.36	2.81	2.52	2.63	1.70	0.92	1.46	—
	3.89	5.33	0.35	2.72	2.44	2.17	1.65	0.90	1.56	—
Key metrics
	9.20	10.98	4.00	7.17	6.83	6.59	5.74	5.72	5.49	—
	21.40%	21.60%	11.70%	16.10%	15.40%	14.90%	13.20%	13.90%	14.00%	—
	9.40%	10.90%	1.10%	6.30%	5.70%	5.90%	3.90%	2.20%	3.70%	—
	—	4.30%	—	2.60%	—	2.40%	—	—	—	—
	-2.80%	14.50%	-21.30%	8.70%	13.00%	—	—	—	—	—
	60.30%	109.90%	-78.80%	205.40%	72.60%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	172.55	173.77	167.94	—
	8.28	7.65	4.24	—
	180.82	181.42	172.17	—
	163.57	166.36	162.88	—
	87.05	87.42	85.12	—
	0.00	0.00	0.00	—
	15.01	15.28	13.74	—
	5.83	5.75	5.91	—
	8.27	8.16	8.33	—
	49.54	49.95	50.91	—
	17.25	15.07	9.30	—
	0.00	0.00	0.00	—
	17.25	15.07	9.30	—
	4.53	3.85	2.59	—
	12.73	11.21	6.71	—
	12.29	10.79	6.12	—
Key metrics
	31.35	28.98	23.54	—
	18.17%	16.70%	14.00%	—
	7.38%	6.50%	4.00%	—
	—	10.10%	7.90%	—
	-0.28%	3.50%	—	—
	63.84%	67.10%	—	—
	—	26.49	15.72	—
	—	3.23	2.69	—
	—	0.32	0.33	—
	—	57.91	54.34	—
	—	82.6	101.6	—
Balance sheet
	—	296.01	268.08	—
	—	91.45	96.62	—
	—	0.22	0.67	—
	—	61.28	61.31	—
	—	20.30	21.11	—
	—	—	11.48	—
	—	86.77	86.86	—
	—	42.23	35.70	—
	—	90.60	75.47	—
	—	58.13	55.01	—
	—	39.15	35.02	—
	—	18.98	19.99	—
	—	179.71	166.32	—
Cash flow
	—	36.16	18.03	—
	—	-33.76	-34.37	—
	—	-2.85	14.81	—
	—	9.67	2.31	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -0.28%
Profit YoY (TTM): +63.84%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +8.83%
Profit YoY (TTM): -346.58%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 50.93%

Quarter	September 2026	June 2026
Promoter %	50.93%	50.93%

Holder	Type	Holding	Previous	Change
TAJOS INVESTMENTS PRIVATE LIMITED	Promoter Group	12.04%	12.04%	0.00%
NANDI SYNTHETICS PVT LTD	Promoter Group	8.83%	8.83%	0.00%
SUNIL LAXMINARYAN MUNDRA	Promoter	5.79%	5.79%	0.00%
SUSHIL KUMAR MUNDRA	Promoter	4.89%	4.89%	0.00%
INDRA MUNDRA	Promoter	3.76%	3.76%	0.00%
SANGEETHA S	Public	3.14%	3.14%	0.00%
JYOTI MUNDRA	Promoter	2.95%	2.95%	0.00%
SHARADA MUNDRA	Promoter	2.55%	2.55%	0.00%
LAXMINARAYAN MOONDRA	Promoter	2.31%	2.31%	0.00%
RADHA S MUNDRA	Promoter	2.30%	2.30%	0.00%
ANURAG SINGHI	Public	1.79%	1.69%	+0.10%
SATYANARAYAN MUNDRA	Promoter	1.78%	1.78%	0.00%
PCG FINVEST PRIVATE LIMITED	Public	1.60%	1.60%	0.00%
SHREY MUNDRA	Promoter	1.59%	1.59%	0.00%
MADHAV MUNDRA	Promoter	1.59%	1.59%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Natural Capsules Ltd.	139	133.20	-5.59	-5.80%	+8.83% TTM	-346.58% TTM	-37.35%

Filings & corporate actions

Recent announcements

This is with reference to the queries/clarification sought by NSE regarding Point F of Explanatory Statement 1 & 2 in relation to the object of the Preferential Issue.4 Nov 2026 · Company Update / General
Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the certificate received from Cameo Corporate Services Limited, Registrar & ....9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We wish to inform that the "Trading Window" for dealing in the equity shares of the company shall remain closed for all Designated Person and their immediate relatives with effect from ....25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Reg 44(3) of SEBI (LODR) Regulations, 2025 , We are Submitting herewith voting results of 1st Extra-Ordinary General Meeting 2026 of the company held on Wednesday, September 20269 Sep 2026 · AGM/EGM / EGM
Pursuant to Regulations 30 of SEBI (LODR) Regulation, 2015 please find the enclosed proceedings of the of 1st Extraordinary General Meeting 2026 of the Company held on Wednesday September ....9 Sep 2026 · AGM/EGM / EGM
Newspaper Publication for Completion of dispatch of Corrigendum Notice of Extraordinary General Meeting ("EGM").3 Sep 2026 · Company Update / Newspaper Publication
We wish to inform you that the company has today, Wednesday, September 02, 2026, completed the dispatch of the Corrigendum to the EGM Notice to all eligible members of the Company.2 Sep 2026 · Company Update / Meeting Updates
1. Approved the Revised Price and Quantity of Equity Shares and Convertible Warrants of Preferential Issue. 2. Approval of the Corrigendum Notice of Extra Ordinary General Meeting.2 Sep 2026 · Board Meeting / Outcome of Board Meeting
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....1 Sep 2026 · Board Meeting / Board Meeting
Copy of Newspaper Publication (i.e., Dispatch of EGM Notice for the attention of the Equity shareholders)19 Aug 2026 · Company Update / Newspaper Publication
Copy of Newspaper Advertisement, i.e Notice for attention of equity shareholders of the company.18 Aug 2026 · Company Update / Newspaper Publication
Cut-off Date (Record Date) for Extraordinary General Meeting ("EGM") is fixed on September 2nd, 2026.18 Aug 2026 · Corp. Action / Record Date
We are hereby submitting the Notice of the Extraordinary General Meeting (EGM) of the Company scheduled to be held on Wednesday, September 09, 2026 at 12:00 PM (IST) through Video Conference ....18 Aug 2026 · AGM/EGM / EGM
This is to inform you that Mr. Pramod Kasat has tendered his resignation from the position of Independent Director of Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), ....17 Aug 2026 · Company Update / General
Approved the Unaudited Consolidated & Standalone Financial Results of the Company for the Quarter ended June 30, 2026.16 Aug 2026 · Result / Financial Results
We hereby inform that the Unaudited Financial Results for the Quarter ended June 30, 2026, has been published in Business Line, an English Daily & Sanjevani a Kannada daily.14 Aug 2026 · Company Update / Newspaper Publication
We are submitting herewith voting results & scrutinizers report of 33rd AGM of Natural Capsules Limited.13 Aug 2026 · AGM/EGM / AGM
Please find enclosed herewith the copy of Investors Presentation in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.13 Aug 2026 · Company Update / Investor Presentation
Please find enclosed herewith the copy of Press Release made to analysts and investors in connection with the Unaudited Consolidated & Standalone Financial Results for quarter ended June 30, 2026.13 Aug 2026 · Company Update / Press Release / Media Release
Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), at its Board Meeting held on today has appointed Mr. K. H. Honneshaiah as the new Chief Operating Officer of the Company.12 Aug 2026 · Company Update / General
1. Approved the unaudited Consolidated & Standalone Financial Results of the Company for the Quarter ended June 30, 2026. 2. Preferential Issue of Equity Shares and Warrants to Promoter.12 Aug 2026 · Board Meeting / Outcome of Board Meeting
33rd Annual General Meeting of the Company held on Wednesday August 12, 2026 at 12.10 P.M. through Video conferencing ("VC") other Audio-visual Means ("OAVM") and was concluded at 01:00 PM.12 Aug 2026 · AGM/EGM / AGM
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Update on board meeting 1. ....9 Aug 2026 · Board Meeting / Board Meeting
Natural Capsules Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve 1. To Consider and approve ....4 Aug 2026 · Board Meeting / Board Meeting
Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), at its Board Meeting held on today, i.e. July 31, 2026, has approved the Allotment of the Right Issue duly approved on ....31 Jul 2026 · Company Update / General
Board of Director of the Company has inter-alia considered and approved a Resolution Passed by Circulation on 28th July, 2026 and the final majority vote was received by 08:00 PM decided ....29 Jul 2026 · Company Update / General
Newspaper Publication for Completion of Dispatch of Notice of 33rd Annual General Meeting and Annual Report for F.Y 2025-26.18 Jul 2026 · Company Update / Newspaper Publication
Annual Report for the Financial Year 2025-26.17 Jul 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 33rd Annual General Meeting ("AGM") of the Company scheduled to be held on Wednesday, August 12, 2026, at 12:00 PM (IST) through Video Conference ("VC") or Other Audio Visual ....17 Jul 2026 · AGM/EGM / AGM
The Record Date for 33rd Annual General Meeting is set on August 05, 2026; Wednesday.17 Jul 2026 · Corp. Action / Record Date
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 - Copy of Newspaper Advertisement, i.e. Notice for attention of equity shareholders ....16 Jul 2026 · Company Update / Newspaper Publication
Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the certificate received from Cameo Corporate Services Limited, Registrar & ....13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is to inform you that under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Natural Biogenex Private Limited ("Material Unlisted Subsidiary"), ....10 Jul 2026 · Company Update / General
This is to inform you that under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015; Natural Biogenex Private Limited (" Material Unlisted Subsidiary"), ....10 Jul 2026 · Company Update / General
Notice to the shareholders for transfer of shares to Investor Education and Protection Fund (IEPF) has been published in Business Line; an English daily and Sanjevani a Kannada daily Newspapers.26 Jun 2026 · Company Update / Newspaper Publication
Closure of Trading Window for dealing in the equity shares of the company shall remain closed for all Designated Person and their immediate relatives with effect from July 01, 2026, till ....25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of transcript of Conference ....3 Jun 2026 · Company Update / Analyst / Investor Meet
Pursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Audio recording of Conference Call held on Tuesday, ....2 Jun 2026 · Company Update / Analyst / Investor Meet
This has reference to our intimation under regulation 30(9) of SEBI (LODR) Regulation, 2015 submitted to the Stock Exchange on May 27, 2026, regarding the outcome of the Board Meeting of ....1 Jun 2026 · Company Update / General
Due to the Technical error in the previously published link for the Conference Call with the Investors/Analysts on the Stock Exchange, we are publishing the corrected link for the upcoming ....1 Jun 2026 · Company Update / Analyst / Investor Meet

Board meetings

12 Aug 2026 Board Meeting - Financial Results